PCYT1A Recombinant Monoclonal Antibody

PCYT1A, also known as choline-phosphate cytidylyltransferase A, catalyzes the rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis. This enzyme plays a central role in membrane lipid homeostasis, making it a compelling target for researchers investigating metabolic regulation, cancer cell proliferation, and neurological function where membrane dynamics are critical.

This recombinant monoclonal antibody, clone 4F2, offers the reproducibility that demanding experimental workflows require. Because it is derived from a defined sequence and produced recombinantly in rabbit, you can expect consistent performance across experiments and between lots, eliminating the variability that can complicate long-term studies or multi-site collaborations. The antibody has been affinity-purified to ensure high specificity for your target.

Validation data demonstrates reliable performance across multiple applications. In western blot analysis of K562 whole cell lysate, the antibody detects a band at the predicted molecular weight of 42 kDa when used at 1:1000 dilution, confirming accurate target recognition. The clean band at expected size indicates specific binding without problematic background. For immunofluorescence studies, testing in HeLa cells at 1:50 dilution reveals clear cellular staining patterns, enabling visualization of PCYT1A localization in fixed and permeabilized samples. The antibody is also validated for ELISA applications, providing flexibility for quantitative detection approaches.

Whether you are exploring lipid metabolism in cancer models, investigating membrane remodeling in neuronal systems, or studying signal transduction pathways that intersect with phospholipid synthesis, this antibody provides a dependable tool for detecting human PCYT1A across your experimental platforms.